Anti-PCSK9 (Lodelcizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC

This ADC product is comprised of an anti-PCSK9 monoclonal antibody conjugated via a MC-Vc-PAB-DMEA-(PEG2) linker to duocarmycin SA. The duocarmycin SA is targeted to ceRoom Temperatureain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, duocarmycin SA binds to DNA, causes DNA damage.